DrugPatentWatch Database Preview
Drugs in Development Information for LGX818
» See Plans and Pricing
What is the development status for investigational drug LGX818?
LGX818 is an investigational drug.
There have been 23 clinical trials for LGX818.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.
There are twenty-nine US patents protecting this investigational drug and four hundred and five international patents.
Summary for LGX818
| US Patents | 29 |
| International Patents | 405 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 553 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 37 |
Recent Clinical Trials for LGX818
| Title | Sponsor | Phase |
|---|---|---|
| BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER) | Merck KGaA, Darmstadt, Germany | Phase 3 |
| BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER) | Ono Pharmaceutical Co. Ltd | Phase 3 |
| BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER) | Pfizer | Phase 3 |
Clinical Trial Summary for LGX818
Top disease conditions for LGX818
Top clinical trial sponsors for LGX818
US Patents for LGX818
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LGX818 | Start Trial | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | Start Trial |
| LGX818 | Start Trial | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | Array BioPharma Inc. (Boulder, CO) | Start Trial |
| LGX818 | Start Trial | Compositions and methods for activating "stimulator of interferon gene"--dependent signalling | ADURO BIOTECH, INC. (Berkeley, CA) | Start Trial |
| LGX818 | Start Trial | Antibody molecules to TIM-3 and uses thereof | Novartis AG (Basel, CH) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) Children's Medical Center Corporation (Boston, MA) | Start Trial |
| LGX818 | Start Trial | Combination therapy with an anti-axl antibody-drug conjugate | ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) | Start Trial |
| LGX818 | Start Trial | Combination therapy | Array BioPharma Inc. (Boulder, CO) | Start Trial |
| LGX818 | Start Trial | Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-iso- propyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | Array BioPharma Inc. (Boulder, CO) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LGX818
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LGX818 | Argentina | AR077975 | 2029-08-28 | Start Trial |
| LGX818 | Australia | AU2010286569 | 2029-08-28 | Start Trial |
| LGX818 | Canada | CA2771775 | 2029-08-28 | Start Trial |
| LGX818 | Chile | CL2012000340 | 2029-08-28 | Start Trial |
| LGX818 | China | CN102725283 | 2029-08-28 | Start Trial |
| LGX818 | China | CN103896921 | 2029-08-28 | Start Trial |
| LGX818 | Colombia | CO6612222 | 2029-08-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
